Background/Objectives: Regional citrate anticoagulation (RCA) is guideline-preferred for continuous renal replacement therapy (CRRT), yet implementation requires expertise, calcium protocols, and reliable monitoring. Evidence for standardized low-molecular-weight heparin strategies without routine anti-Xa monitoring remains limited. Methods: We retrospectively analyzed adult ICU patients receiving protocolized divided-dose enoxaparin during CRRT from January 2020 to December 2024. Enoxaparin 1.5 mg/kg/24 h was divided into six equal prefilter doses every 4 h. The primary outcome was circuit clotting; death and hemodynamic instability were treated as competing termination events. Safety endpoints were ISTH major bleeding, clinically relevant non-major bleeding (CRNMB), minor bleeding, thrombosis, and suspected heparin-induced thrombocytopenia (HIT). Results: The cohort included 200 patients and 223 CRRT runs, contributing 8829.8 CRRT-hours. Median run duration was 35.0 h (IQR, 27.2–52.1). Circuit clotting occurred in 31 runs (13.9%; 95% CI, 9.6–19.1), equivalent to 0.35 events per 100 CRRT-hours. Kaplan–Meier clotting-free survival at 48 h was 89.8% (95% CI, 84.3–95.2), and the competing-risk cumulative incidence of clotting was 9.0%. Any classified bleeding occurred in 10 runs (4.5%; 95% CI, 2.2–8.1), including one ISTH major bleeding event and one CRNMB event. No thrombotic or HIT events were identified. In a prespecified four-variable Cox model with patient-level cluster-robust standard errors, no predictor was significantly associated with clotting. Conclusions: In a citrate-unavailable or citrate-not-routinely-implemented ICU setting, this standardized divided-dose enoxaparin protocol showed low observed major/clinically relevant bleeding rates and acceptable clotting-free circuit performance. Prospective comparative evaluation is warranted.
5 November 2026 in Intensive and Critical Care Nursing
Background and Objectives: Appropriate fluid-removal intensity during continuous renal replacement therapy (CRRT) remains uncertain. We evaluated chart-recorded hourly patient fluid-removal intensity and mortality using a 12 h landmark. Materials and Methods: This retrospective MIMIC-IV v3.1 cohort included adults meeting recorded survival, hospital-observation, and CRRT criteria at the landmark. Exposure was the weight-normalized mean of retained hourly fluid-removal entries over 12 h; equivalence to delivered net ultrafiltration could not be validated. A four-knot restricted cubic-spline logistic model with 26 prespecified adjustment terms assessed 90-day mortality using 50 imputations for missing covariates. Results: Among 1453 patients, 847 (58.3%) had a recorded death within 90 days. Standardized risks were 57.6%, 57.5%, and 58.6% at the 25th percentile, median reference, and 75th percentile. Risk differences versus the reference were +0.1 percentage points (95% confidence interval, −2.4 to +2.6) and +1.1 percentage points (−2.6 to +4.9). Overall association (p = 0.475) and nonlinearity (p = 0.505) were not statistically detectable. Survival and complete-case confidence intervals spanned the null; complete-case uncertainty was greater. Conclusions: Early chart-recorded fluid-removal intensity was not detectably associated with 90-day mortality in this landmark cohort. Intervals remained compatible with clinically important differences; the findings do not define a delivered net-ultrafiltration target.
Background and Objectives: The C-reactive protein-to-albumin ratio (CAR) is associated with mortality and poor outcome after acute ischemic stroke, but the association is not the same as added clinical usefulness. We evaluated whether admission CAR and follow-up CAR provide prognostic information beyond a prespecified parsimonious clinical reference model comprising age, neurological severity, and admission glucose in critically ill patients with acute ischemic stroke. Materials and Methods: In this single-center retrospective cohort of 146 adults with acute ischemic stroke managed in intensive care, CAR was calculated from C-reactive protein and serum albumin at emergency department admission and at the first intensive care laboratory assessment. The primary outcome was 90-day all-cause mortality. A clinical reference model (age, admission National Institutes of Health Stroke Scale [NIHSS] score, admission glucose) was compared with the same model augmented by log-transformed CAR using the area under the receiver operating characteristic curve (AUC), the DeLong test, likelihood-ratio (LR) testing, and bootstrap optimism-corrected performance. Results: Ninety-day mortality occurred in 32 of 146 patients (21.9%) (full cohort; primary complete-case analysis: 141 patients with 31 events). In the primary complete-case analysis (n = 141; 31 events), admission CAR was not independently associated with mortality (odds ratio per 1-SD log CAR 1.46, 95% confidence interval 0.91–2.33; p = 0.115). Adding admission CAR changed the AUC from 0.768 (0.676–0.860) to 0.783 (0.693–0.874) (ΔAUC +0.016, 95% confidence interval −0.024 to +0.055; DeLong p = 0.444; LR p = 0.113), with optimism-corrected point estimates of 0.750 and 0.754. Follow-up CAR did not add value (LR p = 0.159), and change in CAR did not improve discrimination (ΔAUC +0.001; LR p = 0.945); because intensive care sampling times were not standardized, these analyses assess incremental prognostic information rather than CAR kinetics. Admission CAR was not associated with poor 90-day functional outcome (odds ratio 1.09, 95% confidence interval 0.83–1.44; p = 0.530). Conclusions: Admission CAR did not demonstrate measurable incremental prognostic value beyond the prespecified clinical reference model, and follow-up CAR and change-based analyses did not improve prediction, although non-standardized sampling times mean that serial CAR kinetics were not fully evaluated. The confidence intervals remain compatible with both no effect and a positive effect of uncertain clinical relevance, but the observed improvement was insufficient to support CAR as a stand-alone or routinely additive prognostic marker in this setting.
Background: COVID-GRAM predicts composite critical illness. We examined transport of its published linear predictor to in-hospital mortality, mortality-specific recalibration, and the incremental prognostic value of room-air peripheral oxygen saturation (SpO₂) at presentation. Methods: This retrospective secondary analysis used a previously published single-centre cohort from Türkiye (August 2020–January 2021): 294 unique adults and 77 deaths (26.2%). We compared the frozen predictor (M1), intercept-only recalibration (M2), intercept-and-slope recalibration (M3), and M3 plus a three-knot SpO₂ spline (M4), with SpO₂ alone (M0). Performance assessment included discrimination, calibration, Brier score, and exploratory decision curves. Bootstrap internal validation repeated model fitting and empirical knot estimation; two-stage bootstrap procedures quantified uncertainty. Results: M1 had an AUC of 0.883 (95% confidence interval [CI] 0.839–0.927), calibration-in-the-large of 0.076 (− 0.241 to 0.393), and calibration slope of 1.250 (0.946–1.554). Nested comparisons provided insufficient evidence for intercept ( p = 0.639) or slope updating ( p = 0.086). M4 had an apparent AUC of 0.963 and an optimism-corrected AUC of 0.958 (95% bootstrap CI 0.940–0.980). Its corrected AUC exceeded M3 by 0.075 (0.044–0.121); the SpO₂ likelihood-ratio test yielded χ²=82.4 (2 df; p < 0.001). M4’s corrected Brier score was 0.072 (0.049–0.089), and its corrected calibration slope was 0.915. M0’s apparent AUC was 0.908; the COVID-GRAM linear predictor added information beyond M0 (χ²=62.9, 1 df; p < 0.001). Decision-curve findings remained exploratory. Conclusions: Within this historical cohort, room-air SpO₂ provided additional prognostic information beyond the COVID-GRAM predictor after mortality-specific recalibration. The additional complexity and data requirements of M4 have not been shown to provide clinically meaningful benefit over SpO₂ alone. The small sample, retrospective ascertainment, and shared model-fitting and evaluation cohort limit interpretation. These internally assessed results do not establish transportable mortality risks or clinical usefulness; independent contemporary external validation is required.